Opioid Use Disorder Research Study
Researchers at Arch Clinical Trials are conducting a study to assess whether two different treatments for opioid use disorder are equally effective and produce similar results.
Fast Facts
Diagnosed With Moderate or Severe Opioid Use Disorder (OUD)
Currently Dependent on Opioids and Interested in Receiving Buprenorphine Treatment
Compensation Provided
Conducted in
St. Louis, MO
Study Background
At Arch Clinical Trials, our goal is to advance innovative treatment solutions for opioid use disorder through rigorous and impactful research.
This important Phase I study is testing whether two versions of CAM2038, a treatment for opioid addiction, are equally effective and safe. CAM2038 comes in both weekly (32mg) and monthly (128mg) doses, offering flexible options for those in treatment. It’s crucial to ensure both versions work the same way to provide consistent, reliable care for patients.
Participants will go through three stages in the study—Screening, Treatment, and Follow-up—over 6 weeks. During the Treatment phase, they’ll stay at a Clinical Research Unit for five days, where their safety, comfort, and treatment progress will be closely monitored. This includes checking for withdrawal symptoms and analyzing blood samples to measure medication levels.
By joining this study, participants are helping improve opioid use disorder treatments and contribute to better patient care worldwide.
Study Background
At Arch Clinical Trials, our goal is to advance innovative treatment solutions for opioid use disorder through rigorous and impactful research.
This important Phase I study is testing whether two versions of CAM2038, a treatment for opioid addiction, are equally effective and safe. CAM2038 comes in both weekly (32mg) and monthly (128mg) doses, offering flexible options for those in treatment. It’s crucial to ensure both versions work the same way to provide consistent, reliable care for patients.
Participants will go through three stages in the study—Screening, Treatment, and Follow-up—over 6 weeks. During the Treatment phase, they’ll stay at a Clinical Research Unit for five days, where their safety, comfort, and treatment progress will be closely monitored. This includes checking for withdrawal symptoms and analyzing blood samples to measure medication levels.
By joining this study, participants are helping improve opioid use disorder treatments and contribute to better patient care worldwide.
Additional Information
This study is being conducted to determine whether two versions of CAM2038, a treatment for opioid addiction made by different companies, are equally effective and safe. The goal is to ensure that both versions provide the same level of treatment quality to help improve patient outcomes.
You may qualify for a study if you meet the following criteria:
Inclusion Criteria:
- Are diagnosed with moderate to severe opioid use disorder
- Currently dependent on opioids and interested in receiving treatment
- Self-reported opioid use for at least 21 days in the 30 days prior to screening
- Are willing to abstain from short-acting opioids (6+ hours) and long-acting opioids (24–36 hours) before the study
- Have a positive urine drug screen for opioids at screening or display physical signs of withdrawal as determined by the investigator
Exclusion Criteria:
- History or presence of any significant psychiatric, endocrine, hematologic, hepatic, cardiac, or other major illness that may compromise your safety or the study results
If you choose to participate in this study, here’s what you can expect:
Screening Phase:
- You will undergo initial assessments to confirm eligibility, including medical history, physical exams, and a urine drug screen.
- You’ll need to abstain from short-acting opioids for at least 6 hours and long-acting opioids for 24–36 hours before your first study visit.
Treatment Phase:
- You will stay in the Clinical Research Unit (CRU) for five days.
- During this stay, you’ll receive a single dose of the study medication (CAM2038) and be closely monitored by medical professionals for safety and tolerability.
- Blood samples will be collected at various intervals (pre-dose and up to 120 hours post-dose) to assess the medication’s pharmacokinetics (how the drug moves through your body).
Follow-Up Phase:
- After completing the treatment phase, you’ll have follow-up visits to monitor your health and gather any final data for the study.
- You’ll be compensated $180 per night for overnight stays and $140 for outpatient visits.
- Transportation to and from the study site will be provided through Lyft, ensuring convenience and accessibility.
There is no cost for you to participate in our research study.